Japanese encephalitis virus (JEV) is a mosquito-borne virus endemic to China and Southeast Asia that causes severe encephalitis in <1% of infected persons. Transmission of JEV via blood transfusion has not been reported. We report transmission of JEV via blood donation products from an asymptomatic viremic donor to 2 immunocompromised recipients. One recipient on high-dose immunosuppressive drugs received JEV-positive packed red blood cells after a double lung transplant; severe encephalitis and a poor clinical outcome resulted. JEV RNA was detected in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid specimens. The second recipient had leukemia and received platelets after undergoing chemotherapy. This patient was asymptomatic; JEV infection was confirmed in this person by IgM seroconversion. This study illustrates that, consistent with other pathogenic flaviviruses, JEV can be transmitted via blood products. Targeted donor screening and pathogen reduction technologies could be used to prevent transfusion-transmitted JEV infection in highly JEV-endemic areas.

Japanese encephalitis virus (JEV) is a member of the genus *Flavivirus* and is the eponymous member of the JEV antigenic complex of viruses that also includes West Nile virus (WNV). JEV is endemic to Southeast Asia and China, where ≈67,900 cases occur every year (1). The virus is maintained in a complex enzootic cycle involving pigs and birds; humans are infected via the bite of infected *Culex* spp. mosquitoes (particularly *C. tritaeniorhynchus*) (2). Humans infected with JEV have low viremia levels and are considered to be dead-end hosts (3). Although neurologic manifestations are observed in <1% of infected patients, encephalitis caused by JEV is a devastating condition with a mortality rate of 20%–30%. Survivors often suffer permanent neurologic sequelae. No treatment has been proven to be effective for Japanese encephalitis in clinical trials (4).

Arthropodborne viruses are an emerging threat to the blood supply. Transmission via blood transfusion has been described for 4 arthropodborne viruses: dengue virus, WNV, tick-borne encephalitis virus, and Zika virus (5–10). Furthermore, chikungunya virus and Usutu virus have also been found in blood donor samples, indicating a risk for transmission via this route as well (11,12). In contrast, transfusion-related JEV transmission has not been reported in the literature, although the potential for this type of transmission has been recognized (13). In this study, we describe a case of nosocomial Japanese encephalitis in an immunocompromised lung transplant recipient. An outbreak investigation was conducted to ascertain the source of the infection and if other patients were at risk for Japanese encephalitis.

Materials and Methods

Setting

Queen Mary Hospital is a 1,700-bed, university-affiliated, tertiary referral center in Hong Kong that has a lung transplantation service. After lung transplantation, patients are transferred for extended care to Grantham Hospital, a 388-bed specialized respiratory care hospital in the healthcare network of Hong Kong West Cluster.

Virologic Investigations

Virologic investigations for JEV were performed at the Public Health Laboratory Services Branch, Centre for Health Protection, of the Hong Kong Department of Health and the microbiology laboratory at Queen Mary Hospital. We performed JEV IgM testing on serum and cerebrospinal fluid (CSF) using the JE Detect IgM Antibody Capture ELISA (InBiOS, Seattle, WA, USA). We amplified flavivirus RNA in clinical specimens using a conventional

---

Japanese encephalitis virus (JEV) is a mosquito-borne virus endemic to China and Southeast Asia that causes severe encephalitis in <1% of infected persons. Transmission of JEV via blood transfusion has not been reported. We report transmission of JEV via blood donation products from an asymptomatic viremic donor to 2 immunocompromised recipients. One recipient on high-dose immunosuppressive drugs received JEV-positive packed red blood cells after a double lung transplant; severe encephalitis and a poor clinical outcome resulted. JEV RNA was detected in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid specimens. The second recipient had leukemia and received platelets after undergoing chemotherapy. This patient was asymptomatic; JEV infection was confirmed in this person by IgM seroconversion. This study illustrates that, consistent with other pathogenic flaviviruses, JEV can be transmitted via blood products. Targeted donor screening and pathogen reduction technologies could be used to prevent transfusion-transmitted JEV infection in highly JEV-endemic areas.

Japanese encephalitis virus (JEV) is a member of the genus *Flavivirus* and is the eponymous member of the JEV antigenic complex of viruses that also includes West Nile virus (WNV). JEV is endemic to Southeast Asia and China, where ≈67,900 cases occur every year (1). The virus is maintained in a complex enzootic cycle involving pigs and birds; humans are infected via the bite of infected *Culex* spp. mosquitoes (particularly *C. tritaeniorhynchus*) (2). Humans infected with JEV have low viremia levels and are considered to be dead-end hosts (3). Although neurologic manifestations are observed in <1% of infected patients, encephalitis caused by JEV is a devastating condition with a mortality rate of 20%–30%. Survivors often suffer permanent neurologic sequelae. No treatment has been proven to be effective for Japanese encephalitis in clinical trials (4).

Arthropodborne viruses are an emerging threat to the blood supply. Transmission via blood transfusion has been described for 4 arthropodborne viruses: dengue virus, WNV, tick-borne encephalitis virus, and Zika virus (5–10). Furthermore, chikungunya virus and Usutu virus have also been found in blood donor samples, indicating a risk for transmission via this route as well (11,12). In contrast, transfusion-related JEV transmission has not been reported in the literature, although the potential for this type of transmission has been recognized (13). In this study, we describe a case of nosocomial Japanese encephalitis in an immunocompromised lung transplant recipient. An outbreak investigation was conducted to ascertain the source of the infection and if other patients were at risk for Japanese encephalitis.

Materials and Methods

Setting

Queen Mary Hospital is a 1,700-bed, university-affiliated, tertiary referral center in Hong Kong that has a lung transplantation service. After lung transplantation, patients are transferred for extended care to Grantham Hospital, a 388-bed specialized respiratory care hospital in the healthcare network of Hong Kong West Cluster.

Virologic Investigations

Virologic investigations for JEV were performed at the Public Health Laboratory Services Branch, Centre for Health Protection, of the Hong Kong Department of Health and the microbiology laboratory at Queen Mary Hospital. We performed JEV IgM testing on serum and cerebrospinal fluid (CSF) using the JE Detect IgM Antibody Capture ELISA (InBiOS, Seattle, WA, USA). We amplified flavivirus RNA in clinical specimens using a conventional

---

1These authors contributed equally to this article.
panflavivirus heminested reverse transcription PCR (RT-PCR) with primers targeting the nonstructural protein 5 (NS5) gene as described previously (14). We detected RT-PCR products using gel electrophoresis after the first and second rounds of amplification. We performed real-time RT-PCR specific for JEV using an in-house-developed assay with primers targeting the NS5 gene (forward primer 5′-GGAGCTGGATGGAATGTGAA-3′, reverse primer 5′-TCCCTCAGTGGAAGTATAAGA-3′, probe 6-FAM-CCAAGCGTATGCACAGATGTGGC-BBQ-650; online Technical Appendix 1, https://wwwn.cdc.gov/EID/article/24/1/17-1297-Techapp1.pdf). We tested for other pathogens that can cause encephalitis, including herpes simplex virus, varicella zoster virus, enterovirus, adenovirus, cytomegalovirus, erythroparvovirus B19, rabies virus, *Mycobacterium tuberculosis*, *Mycoplasma pneumoniae*, and *Toxoplasma gondii*, using in-house–developed PCR and RT-PCR assays (15).

**Sequencing and Phylogenetic Analysis**

Using the inner primer pairs of the panflavivirus heminested RT-PCR, we performed Sanger sequencing of flavivirus NS5 gene amplicons with the ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). We compared the resulting sequences to the sequences in GenBank using BLAST (16) and performed phylogenetic analysis using MEGA 6.06 (http://www.megasoftware.net/). We performed multiple alignment with the NS5 gene sequences obtained from this study (167 nt long) and those of other JEV strains using ClustalW, followed by phylogenetic tree construction using a Kimura 2-parameter substitution model plus invariant site and the maximum-likelihood method as previously described (17–19).

**Case Definitions**

Patients were defined as having JEV infection if any 1 of 2 laboratory criteria was met: detection of JEV-specific IgM in CSF or serum specimens, or detection of JEV RNA in blood or CSF specimens. Patients were defined as having a confirmed transfusion-transmitted JEV infection if they met the above laboratory criteria for JEV infection and received a blood product transfusion from a donor with JEV viremia during the 3 weeks before illness onset. We performed phylogenetic analysis to compare the blood donor and recipient JEV sequences whenever sequences were available.

**Outbreak Investigation**

Clinical details of the index patient, including date of transplantation, dates of blood transfusions, immunosuppressant dosages, and laboratory investigation results, were retrieved from the electronic patient record system. Archived clinical specimens from the index patient, including serum, CSF, bronchoalveolar lavage fluid, feces, urine, and saliva samples, were retrieved from the microbiology laboratory at Queen Mary Hospital and tested using the panflavivirus heminested PCR assay.

We retrieved details on the organ donor and other transplant recipients from the organ donor registry. We retrieved the remaining blood products of persons who donated blood that was transfused into the index patient during the 3 weeks before illness onset from the Hong Kong Red Cross Blood Transfusion Service and tested these samples using the panflavivirus RT-PCR and JEV-specific RT-PCR described previously.

Because the index patient had resided in Grantham Hospital for the entire JEV incubation period, mosquito presence in Grantham Hospital was directly assessed by interviewing healthcare workers, as described in our previous outbreak investigations (20–23). Culex vector surveillance is performed by the Food and Environmental Hygiene Department in selected areas of Hong Kong. We were able to retrieve the monthly surveillance data from 1 of their surveillance sites near Grantham Hospital (2.5 km away). This study was approved by the institutional review board of the University of Hong Kong and Hospital Authority Hong Kong West Cluster.

**Results**

**Index Patient**

A 52-year-old man with advanced chronic obstructive pulmonary disease underwent double lung transplantation on May 10, 2017, in Queen Mary Hospital. After transplantation, the patient’s clinical course was complicated by nosocomial pneumonia; *Burkholderia cepacia* and methicillin-resistant *Staphylococcus aureus* were isolated from the patient’s sputum specimens. The infection required a prolonged course of broad-spectrum antimicrobial drugs and ventilator support. Antirejection prophylaxis included tacrolimus (0.5 mg/d), mycophenolate mofetil (250 mg 2×/d), and a tapering course of prednisolone. He was transferred multiple times between Queen Mary Hospital and Grantham Hospital (Figure 1). The patient required transfusions of packed red blood cells for anemia on June 20, 22, and 25 (1 unit/d) in Grantham Hospital.

On July 6 (57 days after transplantation and 11–16 days after transfusions), he had a transient maculopapular rash and fever. Blood tests showed leukocytosis (8.99 × 10⁹ cells/L), neutrophil (7.17 × 10⁹ cells/L), and lymphocyte (1.18 × 10⁹ cells/L) counts within reference ranges. Plasma sodium decreased to 128 mmol/L, and liver and renal function test results were unremarkable. His conscious level progressively deteriorated, and he developed myoclonic jerks 2 days after the onset of rash. Serial blood tests showed transient lymphopenia (0.44 × 10⁹ cells/L) and a drop in platelet count (33 × 10⁹/L).
A lumbar puncture was performed 6 days after symptom onset. The opening pressure was 13.4 cm H₂O (reference range 6‒20 cm H₂O), and the CSF had a total cell count of 20 × 10⁶ cells/L, with a predominance of monocytes (58%) and lymphocytes (35%). CSF protein was elevated (1.61 g/L). Magnetic resonance imaging (MRI) of the brain performed 10 days after symptom onset showed symmetric hyperintensities in the bilateral thalami, substantia nigra, and medial temporal lobes (Figure 2).

In view of the CSF pleocytosis and elevated protein levels, an extensive workup was performed for infectious causes of meningoencephalitis. Gram and Ziehl-Neelsen stains, bacterial and fungal cultures, and the cryptococcal antigen test all gave negative results. PCR for herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, enterovirus, rabies virus, Mycobacterium tuberculosis, Mycoplasma pneumoniae, and Toxoplasma gondii were all negative. Serum PCR screening for adenovirus and erythroparvovirus B19 were also negative (Table). Panflavivirus heminested PCR performed on CSF yielded a positive result, with sequencing of the amplicon confirming the presence of JEV (genotype 1). Archived clinical specimens obtained from the patient during the 2 weeks before symptom onset were retrospectively tested using the panflavivirus heminested RT-PCR. Two serum specimens collected June 26 and 28 (10 and 8 days, respectively, before symptom onset) and a bronchoalveolar lavage fluid specimen collected day 5 after symptom onset also tested positive for flavivirus RNA and were confirmed to be JEV by sequencing (GenBank accession no. MF594404). The patient died on October 1, 2017.

**Outbreak Investigation**

In response to this case of nosocomial acquisition of JEV, the hospital infection control team launched an outbreak investigation in Queen Mary Hospital and Grantham Hospital by tracing the placement of the patient during his entire hospitalization. The index patient was treated in air-conditioned rooms in Queen Mary Hospital and Grantham Hospital throughout his hospitalization. Therefore, mosquitoborne transmission was considered unlikely. Furthermore, a vector surveillance point surveyed by the Food and Environmental Hygiene Department, located 2.5 km from Grantham Hospital, showed that *C. tritaeniorhynchus*...
mosquitoes had not been detected since April 2017. Therefore, alternative sources of infection, including blood transfusion, sharps injury with contaminated blood, and organ transplantation, were considered.

The onset of symptoms in the index patient was 57 days after the transplantation date, longer than the usual 5–15-day incubation period for JEV. The organ donor was a 70-year-old road traffic accident victim. Urgent contact tracing of the recipients who received organs (1 liver and 2 kidneys) from this donor revealed that the recipients were asymptomatic. JEV IgM testing of serum samples from these transplant recipients on day 71 (for the liver transplant recipient), day 76 (for renal transplant recipient 1), and day 83 (for renal transplant recipient 2) after transplantation were all negative. A serum sample from the organ donor was not available for JEV testing.

Because the index patient had received 3 units of packed red blood cells from 3 different donors on 3 different days during the 3 weeks before illness onset (i.e., 1 unit each on June 20, June 22, and June 25), the remaining blood products from all 3 donors were traced from the Hong Kong Red Cross Blood Transfusion Service and samples were taken. Only the sample from the transfusion on June 22 tested positive by both real-time RT-PCR for JEV and conventional heminested PCR for flavivirus. Sequencing of the amplicons obtained by conventional PCR yielded a sequence identical to that obtained from the index patient (Figure 3). Phylogenetic comparison with other JEV sequences from GenBank showed that the index case and blood donor isolates belonged to JEV genotype 1, a circulating genotype common in southern China (24). The blood donor was a 46-year-old man who resided in Tin Shui Wai of the Yuen Long District in the New Territories region of Hong Kong. He had been asymptomatic at the time of blood donation (May 29, 2017) and had no recent travel to JEV-endemic regions outside of Hong Kong. He did not develop any symptoms of Japanese encephalitis after the blood donation. On July 22, a serum sample from the donor tested positive for JEV IgM. He was deferred from donating blood for 1 year.

Figure 2. Magnetic resonance imaging of brain of index patient 66 days after double lung transplantation, Hong Kong, China. Coronal FLAIR (FLuid Attenuation Inversion Recovery sequence) image of the head at the level of the lateral ventricles, thalamus, and midbrain shows high signal at bilateral thalamus, midbrain, and medial temporal lobes.

Evaluation for Secondary Cases
After confirmation that a blood donor was the source of JEV infection in the index patient, we urgently traced other patients who received blood products from this donor and identified 2 recipients (Table). One was a 61-year-old man with newly diagnosed acute myeloid leukemia who had received induction chemotherapy with cytarabine and daunorubicin during May 8–14, 2017; he was transfused with platelets obtained from the viremic blood donor on June 2, 2017. His white blood cell count on the day of platelet transfusion was 3.39 × 10^9 cells/L, and he had severe lymphopenia (0.24 × 10^9 cells/L). His lymphocyte counts steadily rose to 0.95 × 10^9 cells/L 10 days after the transfusion and normalized by the end of June. He was asymptomatic at follow-up 2 months after transfusion. Upon recognition that this patient received a potentially JEV-infected blood product, staff retrieved his archived serum specimens collected before transfusion and 33 and 50 days after transfusion to test for JEV IgM. The serum specimens collected before transfusion tested negative for JEV IgM, but those collected after tested positive, confirming a recent asymptomatic infection probably contracted from the platelet transfusion. JEV RNA was not detected in a urine specimen collected 50 days after or a plasma sample collected 53 days after the transfusion.

The other blood product recipient was a 64-year-old man who was admitted for intracranial hemorrhage. He received a plasma transfusion June 20, 2017, and died July 4, 2017, due to respiratory failure. No serum specimens were available for serologic testing from this patient, and an autopsy was not performed.

Discussion
In our study, we report nosocomial transmission of JEV through blood transfusion products from an asymptomatic viremic donor to 2 immunocompromised persons, resulting in 1 case of severe encephalitis and another asymptomatic infection with seroconversion. JEV has been documented to be exclusively transmitted via the bite of Culex mosquitoes. However, when we diagnosed JEV infection in a
Japanese Encephalitis Virus Transmitted Via Blood

transmitted JEV.

lates in the donor and recipient, confirming transfusion-
analysis showed 100% sequence identity between the iso-
the same donor did not reveal any evidence of JEV infec-
tion, which has been reported for WNV, was considered

Kong showed that adult vector prevalence was low in the
C. tritaeniorhynchus spp. breeding density in the district was not available, a
Furthermore, although real-time information on
such as dengue in nearby Guangzhou Province, China (25).

Moreover, although real-time information on Culex
ing the district was not available, a
C. tritaeniorhynchus mosquito distribution survey in Hong
Kong showed that adult vector prevalence was low in the
Aberdeen area, where Grantham Hospital is located (26).

Because of these circumstances, other sources of
infection were considered. Transmission via organ trans-
plantation, which has been reported for WNV, was considered
(27), but serologic screening of other organ recipients from
the same donor did not reveal any evidence of JEV infec-
tion. Blood product transfusion was then considered as a
possible source of infection. JEV RNA was detected in a
blood donation sample from 1 donor, and phylogenetic
analysis showed 100% sequence identity between the iso-
lates in the donor and recipient, confirming transfusion-
transmitted JEV.

The blood donor resided in Tin Shui Wai of the Yuen
Long District, an area that has been shown to have a high
C. tritaeniorhynchus vector density (26). From January
2003 through June 2017, seventeen cases of locally ac-
quired JEV infection in Hong Kong were recorded by
the Department of Health, and 11 (64.7%) of the 17 pa-
tients resided in Yuen Long District. Therefore, the donor
was likely to have been infected in Tin Shui Wai. This
report illustrates that localized pockets of high JEV ende-
micity can facilitate the transmission of JEV via uncon-
ventional routes.

Arboviruses pose unique threats to the blood supply
(28–30). Compromise of the blood supply by arboviruses
has been well documented during explosive outbreaks of
Zika, dengue, WNV, and chikungunya virus infections in
recent years (11,31). Our findings have major implications
for JEV-endemic areas, where undetected transmission of
JEV by blood transfusion might be widespread because of
high rates of asymptomatic infection in both donors and re-
cipients. In the case we report, 24 days elapsed between the
time of blood donation and transfusion to the index patient,
indicating that the virus can remain viable in packed red
blood cells over a prolonged period of time. Risk assess-
ment of the presence of JEV in the blood supply in JEV-
endemic areas should be undertaken.

Mitigation of such transmission is difficult because
standard measures to protect the blood supply during

<table>
<thead>
<tr>
<th>Variable</th>
<th>Donor</th>
<th>Packed red blood cell recipient (index patient)</th>
<th>Platelet recipient</th>
<th>Plasma recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underlying disease</td>
<td>No history of disease, no recent travel to JEV-endemic regions outside Hong Kong; resides in JEV-endemic area Tin Shui Wai, Yuen Long</td>
<td>End-stage chronic obstructive pulmonary disease with lung transplantation, May 10</td>
<td>Acute myeloid leukemia postinduction chemotherapy with cytarabine and daunorubicin</td>
<td>Intracranial hemorrhage</td>
</tr>
<tr>
<td>Blood donation or transfusion type, date</td>
<td>Blood donation, May 29</td>
<td>Packed red blood cell transfusion, June 22</td>
<td>Platelet transfusion, June 2</td>
<td>Plasma transfusion, June 20</td>
</tr>
<tr>
<td>Pretransfusion IgM serology result, date</td>
<td>Specimen not available</td>
<td>Serum negative, May 31</td>
<td>Serum negative, May 25</td>
<td>Specimen not available</td>
</tr>
<tr>
<td>Posttransfusion IgM serology result, date</td>
<td>Serum positive, July 22</td>
<td>CSF positive, July 11; serum positive, July 15 and 18</td>
<td>Serum positive, July 5 and 22</td>
<td>Specimen not available</td>
</tr>
<tr>
<td>JEV nucleic acid test, specimen type and result, date</td>
<td>Positive archived blood specimen</td>
<td>Positive blood sample, June 26 and 28; positive bronchoalveolar lavage, July 10</td>
<td>Negative plasma sample, July 22; negative urine sample, July 25</td>
<td>Specimen not available</td>
</tr>
<tr>
<td>Clinical symptoms</td>
<td>Asymptomatic</td>
<td>Fever and rash July 6 (14 d after transfusion), followed by decreased consciousness and myoclonic jerks; MRI showed typical appearance of T2 hyperintensity of bilateral thalami, substantia nigra, and medial temporal lobes</td>
<td>Asymptomatic</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

| Outcome | Full recovery | Died October 1, 2017 | Full recovery | Died from respiratory failure 14 d after transfusion |

*CSF, cerebrospinal fluid; JEV, Japanese encephalitis virus; MRI, magnetic resonance imaging.
arboviral outbreaks, such as donor symptom and travel questionnaires (online Technical Appendix 2, https://wwwnc.cdc.gov/EID/article/24/1/17-1297-Techapp2.pdf), are not useful in the case of JEV, which has a high rate of subclinical infection and low incidence in Hong Kong. Two approaches to minimize the risk for transfusion-transmitted JEV infection are donor JEV screening and pathogen reduction technology (PRT). Both approaches have limitations. Donor screening would involve nucleic acid testing (NAT) of either individual donors or multiple donors by using minipools, as has been described for WNV and Zika virus (32–34). The biggest challenge for implementing screening is the lack of well-established and licensed JEV NAT for use in the blood donor setting. The use of clinical diagnostic NAT for donation screening is associated with the potential for false-positive results by cross-contamination caused by amplicon carryover. Individual donor NAT is likely to be prohibitively expensive, and minipool NAT is difficult to standardize for JEV, given the lack of data on viral loads in asymptomatic persons.

Although historically most Japanese encephalitis cases in Hong Kong have occurred during the rainy summer season (May–August), even limited seasonal screening of residents in high-risk areas of Hong Kong might be impractical because of the highly mobile population and imprecise delineation of seasons due to climate change. Although donor screening might not be cost-effective for universal application, a more selective application of blood products used for immunocompromised persons might be considered. However, JEV can cause life-threatening disease even in immunocompetent persons, and the correlation between immunosuppression and disease severity is not clear. A range of novel PRTs for blood products that involve the combined use of ultraviolet light and reagents such as psoralens or riboflavin are available (35,36). Examples include the INTERCEPT Blood System for platelets and plasma (Cerus Corporation, Concord, CA, USA); Mirasol Pathogen Reduction Technology for plasma, platelets, and whole blood (Terumo BCT, Lakewood, CO, USA); and the THERAFLEX platform for
plasma and platelets (Macopharma, Tourcoing, France). These methods require individual component processing, are not suitable for all blood components, and are expensive to implement. No direct evidence indicates that these products are efficient at reducing JEV infectivity, although such efficacy could be extrapolated from studies on PRT for Zika and dengue viruses (37,38). Also, leukocyte depletion of blood products might theoretically reduce the risk for JEV transmission, but this method also requires validation. Implementation of a JEV vaccination program with high coverage in areas with high C. tritaeniorhynchus mosquito breeding density might also be considered to definitively eliminate this virus from the blood supply. If transfusion-transmitted JEV is confirmed to be a significant threat to the blood supply in highly endemic regions, a combination of these methods might be required to prevent transfusion-transmitted JEV infection.

Transmission of WNV, another member of the JEV antigenic serocomplex, to immunocompromised patients via blood transfusion has been reported (7). Immunocompromised patients infected with WNV tended to have longer incubation periods (≥10 days) and higher rates of severe illness (39). In our study, the index patient had symptom onset 14 days after the transfusion and overt encephalitis 2 days later, a relatively long incubation period, comparable with the observations made for WNV. Clinical specimens from immunocompetent patients with JEV infection are typically PCR negative at symptom onset, reflecting immune-mediated pathogenesis of the disease. However, in our immunocompromised patient, JEV RNA was detected in a serum specimen from 10 days before symptom onset and in bronchoalveolar fluid and CSF samples from days 5 and 6, respectively, after symptom onset, reflecting the inability of this immunocompromised patient to effectively clear the virus. The detection of JEV in lower respiratory tract specimens has not been reported previously. However, WNV has been reported to cause pneumonia in immunocompromised transplant recipients (40). The clinical significance of JEV in the respiratory tract of our patient is unclear; the patient had extensive consolidative changes over both lung fields on chest radiograph, but culture of the bronchoalveolar fluid specimen yielded B. cepacia, suggesting a component of bacterial pneumonia. However, pulmonary involvement caused by disseminated JEV infection in this immunocompromised patient cannot be excluded.

We identified a second patient who had evidence of JEV seroconversion after receiving platelets from the viremic donor. This patient was immunocompromised at the time of platelet transfusion, which was 19 days after completion of induction chemotherapy for acute leukemia. His relatively asymptomatic clinical course was probably related to the recovery of bone marrow function during the incubation period, in contrast to the index patient, who was subjected to continuous lymphocyte-depleting immunosuppression from the antirejection prophylaxis administered during the incubation period. However, other factors might be responsible, including differences in virus inoculum (the JEV envelope protein has hemagglutinating properties, which could have resulted in a higher accumulation of virus in the packed red blood cell packet); blood product storage conditions (platelet concentrates are stored at higher temperatures, which could have lowered JEV viability in this blood product); and other subtle differences in host-pathogen interactions.

In summary, this study illustrates that JEV can be transmitted via transfusion of cellular blood components to immunocompromised persons and could cause severe outcomes. Enhanced understanding of the prevalence of JEV in the blood supply, the incidence of transfusion-transmitted JEV, and measures for risk mitigation in JEV-endemic areas are urgently needed.

This work was supported in part by donations from Michael Tong, Providence Foundation Ltd (in memory of the late Lui Hac Minh), and the Hong Kong Hainan Commercial Association and by funding from the Consultancy Service for Enhancing Laboratory Surveillance of Emerging Infectious Diseases of the Department of Health, Hong Kong Special Administrative Region, and the Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the Ministry of Education of China.

Dr. Cheng is a consultant clinical microbiologist and infection control officer at Queen Mary Hospital, Hospital Authority, Hong Kong Special Administrative Region, and honorary professor at the Department of Microbiology at the University of Hong Kong. His major research interests include infection control and clinical infectious diseases. Dr. Sridhar is a clinical assistant professor at the Department of Microbiology of the University of Hong Kong. His major research interests include clinical virology and emerging viruses.

References


Japanese Encephalitis Virus Transmitted Via Blood


Address for correspondence: Kwok-Yung Yuen, Carol Yu Centre for Infection, The University of Hong Kong, University Pathology Building, Queen Mary Hospital Compound, Pokfulam Road, Hong Kong Special Administrative Region, China; email: kyyuen@hku.hk

August 2017: Vectorborne Infections

- Added Value of Next-Generation Sequencing for Multilocus Sequence Typing Analysis of a Pneumocystis jirovecii Pneumonia Outbreak
- Bartonella quintana, an Unrecognized Cause of Infective Endocarditis in Children in Ethiopia
- Characteristics of Dysphagia in Infants with Microcephaly Caused by Congenital Zika Virus Infection, Brazil, 2015
- Zika Virus Infection in Patient with No Known Risk Factors, Utah, USA, 2016
- Acute Febrile Illness and Complications Due to Murine Typhus, Texas, USA
- High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus
- Characterization of Fitzroy River Virus and Serologic Evidence of Human and Animal Infection
- Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine
- Lyme Borreliosis in Finland, 1995–2014
- Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates
- Maguari Virus Associated with Human Disease

Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China

Technical Appendix

One-Step Real-Time Reverse Transcription PCR

To detect Japanese encephalitis virus (JEV), we used RealTime ready RNA Virus Master kit (Roche, Indianapolis, Indiana, USA) and real-time PCR machine LC2.0 (Roche). We used the following primers and probe: JE-F(e) (5′-GGAGCTGGATGGAATGTGAA-3′, 10 μM); JE-R(e) (5′-TCCCTCCGATGGAAGTATAGAA-3′, 10 μM); and JE-P(e) (6-FAM-CCAAAGCGTATGCACAGATGTGGC-BBQ-650, 5 μM). Equine herpes virus primers, probes, and DNA were also included in reactions as a DNA internal control. The thermocycler conditions for the real-time reverse transcription PCR (RT-PCR) were as follows: reverse transcription at 50°C for 15 min; heat inactivation at 95°C for 30 s; 45 cycles of denaturation at 95°C for 1 s, annealing at 55°C for 20 s, and extension at 72°C for 5 s; and cooling at 40°C for 30 s.

The limit of detection of our assay (using a –7 dilution of cell culture extract, cycle threshold (Ct) 36.10–37.50; using a –8 dilution of cell culture extract, Ct 42.60 to undetectable) is comparable with that of the 1-step conventional nested RT-PCR for detection of flaviviruses when tested by using a –8 serial dilution of JEV RNA extracted from a mosquito isolate grown in C6/36 cell culture. Cross reactivity to dengue virus serotypes 1, 2, 3, and 4; chikungunya virus; and West Nile virus was not detected. Archived samples previously positive for JEV (3
mosquito isolates and 2 clinical specimens (brain tissue and cerebrospinal fluid) were all positive by our in-house assay, and 51 JEV-negative archived RNA samples taken from cerebrospinal fluid (3 herpes simplex virus 2–positive, 3 varicella zoster virus–positive, and 45 negative) were retested and still negative by our in-house test. The 1-step real time RT-PCR with internal control has comparable limit of detection as the 1-step conventional nested RT-PCR for detection of flaviviruses and was adopted for routine use in 2014.
Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China

Technical Appendix

The following pages show questionnaire given by Hong Kong Red Cross to blood donors.
HONG KONG RED CROSS
BLOOD TRANSFUSION SERVICE
BLOOD DONATION REGISTRATION FORM

PART I: PRE-DONATION INFORMATION

Thank you for coming to give blood today. Your donation could save and change the lives of the recipients. We sincerely request you to read our blood donation information precisely. To protect your safety in giving blood and the safety of the recipients of your donation, it is vital that we review your suitability to donate today. If you are uncertain about any questions in this form or in need of more blood donation information, please talk to our nurse on duty.

After donation, your blood will be stringently tested, inter alia, blood groups and infectious diseases, before processed into blood products. Donations that meet all the quality and safety standards will be issued for patient use in Hong Kong. However, some will be selected for quality assurance testing, academic or medical research. In addition, it may be made available to patients outside Hong Kong for humanitarian considerations or if there is a genuine surplus to local needs.

Giving blood is not completely risk-free as adverse reactions may occasionally happen. These include bruising, pain, inflammation, infection or skin allergy around the needle puncture site, dizziness or fainting after donation. They usually are mild and short-lasting. In the event of adverse reactions, our nurses will provide on-site care and arrange referral to hospital, if necessary. We sincerely request you to read and follow our “Post-Donation Advice”.

We would use your contact information (name, address, telephone and email) provided in this form to keep you informed of blood donation activities. In addition, if your blood is tested positive for any of the infection, we shall inform you accordingly. Should you have any queries, please feel free to ask our nurse on duty.

SAFE BLOOD SAVE LIVES

NOT ALL BLOOD BORNE INFECTIONS CAN BE DETECTED BY LABORATORY TESTS. PLEASE HELP US ENSURE BLOOD SAFETY AND DO NOT PROCEED TO DONATE IF YOU SUSPECT THAT YOUR BLOOD MAY CARRY A POTENTIAL RISK OF INFECTION OR IF YOU WANT TO HAVE YOUR BLOOD TESTED.

FOR FREE HIV TESTING, PLEASE CONSULT YOUR DOCTOR OR CALL 2780 2211.

If you find this blood donation registration form, please contact our staff at 2710 1333.
PART II: HEALTH SCREENING AND INFECTION RISK ASSESSMENT

You are required to answer the following questions honestly by putting a "✓" in the correct box. If you do not understand any questions in this form or not certain how to respond, please leave the question blank and seek clarification from our nursing staff later. Our nurse will review your responses, answer your questions and discuss with you IN CONFIDENCE to determine if you can donate today. The information you disclose will be kept in strict confidence. Thank you.

<table>
<thead>
<tr>
<th>General Health Screening</th>
<th>YES</th>
<th>NO</th>
<th>Staff Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1. Are you feeling well enough to give blood today?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2. Are you currently under a doctor's treatment, taking any medication (including herbal medicine) or awaiting test result?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A3. Have you ever been diagnosed of the following illnesses?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• cardiovascular diseases (e.g. chest pain, hypertension)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• respiratory diseases (e.g. asthma)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• gastrointestinal or liver diseases (e.g. inflammatory bowel disease, hepatitis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• blood diseases (e.g. bleeding problem)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• cancers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• endocrine or metabolic diseases (e.g. diabetes, thyroid diseases)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• neurological diseases (e.g. loss of consciousness, epilepsy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• mental disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• kidney or urogenital diseases (e.g. nephritis, kidney or bladder stones)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• autoimmune or rheumatological diseases (e.g. SLE, rheumatoid arthritis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A4. Have you ever been diagnosed of G6PD deficiency?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A5. Have you ever taken the following drugs?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• aspirin or any drugs containing aspirin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• non-steroidal anti-inflammatory drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• drugs for hair loss</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• drugs for benign prostatic hypertrophy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• drugs for acne</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A6. Have you ever had drug allergy?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, please specify:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A7. If you are male, please continue the questionnaire on the next page.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If you are female,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Are you pregnant?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Have you given birth/ had an abortion in the last 12 months?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Are you still breast-feeding?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Have you ever received treatment for infertility?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### HIV/AIDS, Hepatitis B and Hepatitis C Infection Risk Assessment (Some of the questions below are related to your sexual life. Sexual contact in this Form refers to oral, vaginal or anal sex, with or without the use of condom.)

<table>
<thead>
<tr>
<th>B1. Have you been diagnosed of or suspected to have the following?</th>
<th>YES</th>
<th>NO</th>
<th>Staff Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>• HIV infection/ AIDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Hepatitis B infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Hepatitis C infection</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| B2. Have you ever had sex for money?                          |     |    |           |

| B3. Have you ever used or injected yourself with narcotics or non-prescribed medication? |     |    |           |

| B4. Have you ever received clotting factor concentrates?      |     |    |           |

| B5. Are you aware of your sexual partner(s)                   |     |    |           |
| • has been diagnosed of HIV infection/ AIDS?                  |     |    |           |
| • has ever been a sex worker?                                 |     |    |           |
| • has ever used or injected narcotics or non-prescribed medication? |     |    |           |
| • has ever received clotting factor concentrates?             |     |    |           |

| B6. If you are male, have you ever had oral or anal sex with a man? |     |    |           |
| • If you are female, have you ever had sexual contact with a bisexual man (one who has had oral or anal sex with another man)? |     |    |           |

### CJD and vCJD (Mad-cow Disease) Infection Risk Assessment

<table>
<thead>
<tr>
<th>C1. Between 1 January 1980 and 31 December 1996,</th>
<th>YES</th>
<th>NO</th>
<th>Staff Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>• have you spent a total of three or more months in the UK?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• have you worked or lived for a total of six or more months at US Military bases in Europe?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| C2. Between 1 January 1980 and the present,                  |     |    |           |
| • have you spent a total of five or more years in Europe?    |     |    |           |
| • have you received blood transfusion in the UK or France?  |     |    |           |
| • have you received bovine insulin injection?                |     |    |           |

| C3. Have you ever received                                   |     |    |           |
| • pituitary derived human growth hormone or human gonadotrophin? |     |    |           |
| • organ or tissue transplant?                                |     |    |           |

<p>| C4. Have any of your blood relatives been diagnosed of Creutzfeldt-Jakob Disease (CJD)? |     |    |           |</p>
<table>
<thead>
<tr>
<th>Other Recent Infection or Vaccination Risk Assessment</th>
<th>YES</th>
<th>NO</th>
<th>Staff Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D1. In the past 1 week,</strong> have you had any dental procedure (including scaling, dental extraction, etc.), open wounds or skin lesions?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D2. In the past 2 weeks,</strong> have you had symptoms of flu, fever, headache, eye pain, muscle or joint pain, vomiting, enlarged lymph nodes or skin rash?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **D3. In the past 4 weeks,**  
  - have you had contact with someone with an infectious disease e.g. chickenpox, rubella, tuberculosis (TB)?  
  - have you had any vaccinations e.g. vaccination against Hepatitis A, Hepatitis B or tetanus?  
  - have you had diarrhea? |     |    |           |
| **D4. In the past 12 months,**  
  - have you travelled outside Hong Kong?  
    Destination(s): ___________________________  
    Date of return to HK (DD/MM/YY):____________  
  - have you had tattoo, acupuncture, ear or body piercing, or accidental needle stick injury?  
  - have you been given Hepatitis B Immune Globulin?  
  - have you been bitten by any animal?  
  - have you undergone surgical operation (including endoscopic examination, treatment involving the use of catheters)?  
  - have you received blood transfusion? |     |    |           |
| **D5. Have you been diagnosed of the following infectious diseases?**  
  - Malaria  
  - Venereal disease  
  - Tuberculosis (TB)  
  - Glandular fever  
  - SARS  
  - Dengue Fever  
  - West Nile Virus Infection  
  - Chikungunya  
  - Others, please specify: |     |    |           |
### Other Risk Factors Assessment

<table>
<thead>
<tr>
<th>Question</th>
<th>YES</th>
<th>NO</th>
<th>Staff Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1. Have you ever donated blood under another name?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2. Have you ever been informed not to donate blood permanently by us or other blood service?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E3. Have you resided outside Hong Kong consecutively for 6 months or longer during the past three years?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, your previous country of residence:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E4. Will you be undertaking any hazardous sport today? e.g. rock climbing, diving or flying</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E5. Will you be driving a heavy vehicle or working at hazardous depths or heights today? e.g. fireman, train or lorry driver, or scaffolding worker</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Supplementary Question

<table>
<thead>
<tr>
<th>Question</th>
<th>YES</th>
<th>NO</th>
<th>Staff Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1. Are you aware of your sexual partner(s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Has been diagnosed of Zika infection?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Has been resided or returned from the Zika virus affected areas in the past 3 months?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PART III: DECLARATION

I solemnly and sincerely declare that I have read, understood and agreed with 'Part I: PRE-DONATION INFORMATION' and the staff on duty has answered all my queries.

I solemnly and sincerely declare that all information which I have provided in 'Part II: HEALTH SCREENING AND INFECTION RISK ASSESSMENT' is true. I also consent to have my blood tested for infectious diseases (including HIV) by the Hong Kong Red Cross Blood Transfusion Service and to be informed if my blood is tested positive.

Donor Signature: ____________ Date: ____________ Screening nurse Signature: ____________

(please sign in front of screening nurse)
PART IV : PERSONAL INFORMATION

(Corresponds to Personal Identity Document) (Remark: Photocopy of form is not accepted.)
If there is no change of contact details, previous donors are required to fill items with * asterisk only:

*Name
Surname
Other Name

Name in Chinese ___________________________ Telegraph code(___________________________)
(if applicable) (if applicable)

*HK ID. No. ___________________________ *Date of Birth (DD) (MM) (YY)

*Weight (kg) *Height (cm) Blood Group Donor ID.

Have you donated blood in HK
Yes ☐ No ☐ *

Last Donation Date

Corresponding Address
(Please provide accurate address for future correspondence)

H.K. ☐ KLN. ☐ N.T. ☐

Daytime Tel. No. _______________ Nighttime Tel. No. _______________

*Mobile No. _______________

Email Address _______________

☐ I do not wish to receive information relating to the publicity and promotion of blood donation activities.

For Office Use Only
(Please of where appropriate)

Donor Examination

Hb TestPerformed By

Bld. mmHg P________/min.

Hb/Counter Reading

(highlight heading when out of range)

/ g/dl ___________ ___________ ___________ ___________ 0°C

Hb/Counter Eq. No. EHMC

EBAC

Apheresis

Plasma only ☐ Platelet only ☐

Plasma & Platelet ☐

Time Hb tested ___________ hr. min.

Blood Unit Weigher Equipment No. EIMIX /EIBAI /EICFP

Hand Held Sealer Equipment No. EITCS

No. of DIN Labels Used / Destroyed /

Blood Flow

Blood Pack (WB Donation) Volume Collected

Start Time ___________ hr. min. Quadruple 450 □ Over Collection________ml

End Time ___________ hr. min. Quadruple 350 □ Low Volume Unit________ml

Duration ___________ min. Single □ Inadequate Collection________ml

Fail________ml □

Health Screened By:

Staff Code

Access for Venepuncture

11/RI (1°) 11/RI (2°)

(1°) (2°)

Special Message:

Accepted for Donation and Venepuncture By:

Venepuncture Completed By:

☐ Deferral ☐ Hold ☐ Remark Code: Deferral Duration:

Comment:

WBCS281F1_19

Page 7 of 7